BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amerikanou C, Dimitropoulou E, Gioxari A, Papada E, Tanaini A, Fotakis C, Zoumpoulakis P, Kaliora AC. Linking the IL-17A immune response with NMR-based faecal metabolic profile in IBD patients treated with Mastiha. Biomed Pharmacother 2021;138:111535. [PMID: 34311533 DOI: 10.1016/j.biopha.2021.111535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Soulaidopoulos S, Tsiogka A, Chrysohoou C, Lazarou E, Aznaouridis K, Doundoulakis I, Tyrovola D, Tousoulis D, Tsioufis K, Vlachopoulos C, Lazaros G. Overview of Chios Mastic Gum (Pistacia lentiscus) Effects on Human Health. Nutrients 2022;14:590. [DOI: 10.3390/nu14030590] [Reference Citation Analysis]
2 Amerikanou C, Papada E, Gioxari A, Smyrnioudis I, Kleftaki SA, Valsamidou E, Bruns V, Banerjee R, Trivella MG, Milic N, Medić-Stojanoska M, Gastaldelli A, Kannt A, Dedoussis GV, Kaliora AC; MAST4HEALTH. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. Pharmacol Res 2021;171:105753. [PMID: 34224858 DOI: 10.1016/j.phrs.2021.105753] [Reference Citation Analysis]
3 Wang Y, Huang B, Jin T, Ocansey DKW, Jiang J, Mao F. Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy. Front Immunol 2022;13:835005. [DOI: 10.3389/fimmu.2022.835005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]